|
| 37487665 | Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development. | J Immunother Cancer | 2023 |
| 35074903 | Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. | J Immunother Cancer | 2022 |
| 35662283 | Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. | Nat Med | 2022 |
| 35362046 | Hallmarks of Resistance to Immune-Checkpoint Inhibitors. | Cancer Immunol Res | 2022 |
| 35449104 | The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021. | J Transl Med | 2022 |
| 36052496 | Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. | Cancer Res | 2022 |
| 36052495 | Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. | Cancer Res | 2022 |
| 33387490 | CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. | Lancet Oncol | 2021 |
| 34261774 | Correction: Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV<sup>+</sup> Patients. | Clin Cancer Res | 2021 |
| 32238470 | Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. | J Immunother Cancer | 2020 |
| 30755306 | It Is a Capital Mistake to Theorize Who to Treat with Checkpoint Inhibitors before One Has Data. | Trends Cancer | 2019 |
| 31235758 | HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma. | Sci Rep | 2019 |
| 31308059 | Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients. | Clin Cancer Res | 2019 |
| 29440171 | Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. | Cancer Res | 2018 |
| 27815356 | KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells. | Clin Cancer Res | 2017 |
| 28138031 | Anti-KIT Monoclonal Antibody Treatment Enhances the Antitumor Activity of Immune Checkpoint Inhibitors by Reversing Tumor-Induced Immunosuppression. | Mol Cancer Ther | 2017 |
| 28723928 | ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC. | PLoS One | 2017 |
| 27986750 | Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV<sup>+</sup> Patients. | Clin Cancer Res | 2017 |
| 27349976 | Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors. | Immunotherapy | 2016 |
| 27279243 | Emerging Receptor Tyrosine Kinase Drug Targets: Implications for Antibody-Based Therapies for Oncology and Immunologic Disorders. | Crit Rev Oncog | 2015 |
| 23090886 | Pharmacokinetic and pharmacodynamic comparability study of moxetumomab pasudotox, an immunotoxin targeting CD22, in cynomolgus monkeys. | J Pharm Sci | 2013 |
| 23990866 | Circulating tumor cells: application as a biomarker for molecular characterization and predictor of survival in an all-comer solid tumor phase I clinical study. | PLoS One | 2013 |
| 22327175 | MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. | Int J Oncol | 2012 |
| 22070056 | CD22 as a target for cancer therapy. | J Exp Ther Oncol | 2011 |
| 22046260 | Altered expression of insulin receptor isoforms in breast cancer. | PLoS One | 2011 |
| 19782564 | Synthesis, antiproliferative, and pharmacokinetic properties of 3- and 17-double-modified analogs of 2-methoxyestradiol. | Bioorg Med Chem Lett | 2009 |
| 19901556 | The hematopoietic-specific beta1-tubulin is naturally resistant to 2-methoxyestradiol and protects patients from drug-induced myelosuppression. | Cell Cycle | 2009 |
| 19762246 | Synthesis of 2- and 17-substituted estrone analogs and their antiproliferative structure-activity relationships compared to 2-methoxyestradiol. | Bioorg Med Chem | 2009 |
| 19782568 | Synthesis and antitumor activities of 3-modified 2-methoxyestradiol analogs. | Bioorg Med Chem Lett | 2009 |
| 18566218 | Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198. | Mol Cancer Ther | 2008 |
| 17158205 | 2-methoxyestradiol induces mammary gland differentiation through amphiregulin-epithelial growth factor receptor-mediated signaling: molecular distinctions from the mammary gland of pregnant mice. | Endocrinology | 2007 |
| 17910916 | Synthesis and structure-activity relationships of 16-modified analogs of 2-methoxyestradiol. | Bioorg Med Chem | 2007 |
| 17932327 | Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia. | Circ Res | 2007 |
| 17178898 | Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. | Cancer Res | 2006 |
| 16230404 | beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells. | Cancer Res | 2005 |
| 12543804 | 2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. | Cancer Res | 2003 |
| 12726862 | 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. | Cancer Cell | 2003 |
| 12097276 | 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. | Cancer Res | 2002 |
| 11191057 | 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. | Cancer Metastasis Rev | 2000 |
| 9712835 | Synaptotagmin-1 is required for fibroblast growth factor-1 release. | J Biol Chem | 1998 |
| 9647656 | Activation of the MAP kinase pathway by FGF-1 correlates with cell proliferation induction while activation of the Src pathway correlates with migration. | J Cell Biol | 1998 |
| 9712836 | S100A13 is involved in the regulation of fibroblast growth factor-1 and p40 synaptotagmin-1 release in vitro. | J Biol Chem | 1998 |
| 9712834 | The extravesicular domain of synaptotagmin-1 is released with the latent fibroblast growth factor-1 homodimer in response to heat shock. | J Biol Chem | 1998 |
| 8662999 | The nuclear trafficking of extracellular fibroblast growth factor (FGF)-1 correlates with the perinuclear association of the FGF receptor-1alpha isoforms but not the FGF receptor-1beta isoforms. | J Biol Chem | 1996 |
| 8960122 | Identification and functional characterization of a highly conserved sequence in the intron of the kappa light chain gene. | Mol Immunol | 1996 |